9.40

1.47% -0.14

After Hours: 9.40

Kura Oncology Inc (KURA)

Overview News Price History Option Chain Financials Discussions Forecast

Kura Oncology Inc stock is traded at $9.40, with a volume of 1.01M. It is down -1.47% in the last 24 hours and up +1.95% over the past month. Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

Previous Close:

$9.54

Open:

$9.56

24h Volume:

1.01M

Relative Volume:

0.62

Market Cap:

$834.48M

Revenue:

$71.64M

Net Income/Loss:

$-294.57M

P/E Ratio:

-2.8076

EPS:

-3.348

Net Cash Flow:

$-84.46M

1W Performance:

+6.70%

1M Performance:

+1.95%

6M Performance:

-11.57%

1Y Performance:

+44.84%

1-Day Range:

$9.16

$9.605

1-Week Range:

$8.51

$9.64

52-Week Range:

$5.45

$12.49

Kura Oncology Inc Stock (KURA) Company Profile

Name

Kura Oncology Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

(858) 500-8800

Address

4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA

Employee

260

Twitter

@kuraoncology

Next Earnings Date

2026-08-06

Latest SEC Filings

KURA's Discussions on Twitter

Compare KURA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KURA Kura Oncology Inc	9.40	846.91M	71.64M	-294.57M	-84.46M	-3.348
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Initiated	Lake Street	Buy
Sep-04-25	Initiated	Guggenheim	Neutral
Feb-06-25	Downgrade	BTIG Research	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy
Oct-14-24	Downgrade	Stifel	Buy → Hold
Dec-22-23	Initiated	Mizuho	Buy
Aug-11-23	Initiated	BofA Securities	Buy
Jul-27-23	Initiated	Scotiabank	Sector Perform
May-17-23	Initiated	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight
Feb-15-22	Initiated	Jefferies	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Dec-07-20	Reiterated	H.C. Wainwright	Buy
Dec-03-20	Initiated	Stifel	Buy
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform
May-05-20	Initiated	Barclays	Overweight
Jul-18-19	Initiated	Deutsche Bank	Buy
Nov-09-18	Initiated	Piper Jaffray	Overweight
Aug-01-18	Initiated	H.C. Wainwright	Buy
Oct-13-16	Resumed	Leerink Partners	Outperform
Jan-22-16	Initiated	JMP Securities	Mkt Outperform
Dec-30-15	Initiated	Oppenheimer	Outperform
Dec-16-15	Initiated	Citigroup	Buy

View All

Kura Oncology Inc Stock (KURA) Latest News

Jun 15, 2026

KURA Reiterates by Citizens -- Price Target Maintained at $24.00 - GuruFocus

Jun 15, 2026

Citizens reiterates Kura Oncology stock rating on strong trial data - Investing.com

Jun 15, 2026

Citizens reiterates Kura Oncology stock rating on strong trial data By Investing.com - Investing.com Canada

Jun 15, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 15, 2026

Jun 13, 2026